Gastric Sleeve Surgery in India and UAE | Complete Patient Guide

ELIGIBLE CANDIDATES:

• BMI ≥ 40 kg/m² without comorbidities

• BMI ≥ 35 kg/m² with at least one significant obesity-related comorbidity: Type 2 diabetes mellitus, hypertension, obstructive sleep apnea (OSA), obesity hypoventilation syndrome, non-alcoholic steatohepatitis (NASH), gastroesophageal reflux disease (GERD — relative), hyperlipidemia, or degenerative joint disease

• BMI 30–34.9 kg/m² with inadequately controlled Type 2 diabetes or metabolic syndrome (considered on a case-by-case basis per recent IFSO/ADA guidelines)

• Age 18–65 years (exceptions considered for adolescents with severe comorbidities or patients >65 after thorough cardiopulmonary risk assessment)

• Documented failure of supervised non-surgical weight loss attempts for a minimum of 6–12 months

• Psychological clearance: no active untreated eating disorder (binge eating disorder requires pre-operative CBT), no active substance dependence, and stable psychiatric status

• Motivated patient with demonstrated understanding of lifelong dietary and supplementation commitments

REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Upper GI Endoscopy (EGD): mandatory to rule out Helicobacter pylori infection, esophagitis, Barrett's esophagus, hiatal hernia, and gastric lesions

• Abdominal Ultrasound: assessment of hepatic steatosis, gallstones, and hepatomegaly

• Polysomnography (Sleep Study): indicated if OSA is clinically suspected

• Full Blood Panel: CBC, CMP, HbA1c, fasting insulin, lipid profile, thyroid function (TSH/fT4), iron studies, Vitamin B12, Vitamin D (25-OH), folate, and coagulation screen (PT/INR/aPTT)

• Cardiac Evaluation: 12-lead ECG; Echocardiogram (2D ECHO) if BMI > 50, age > 45, or cardiovascular risk factors present; stress testing where indicated

• Pulmonary Function Tests (PFTs): for patients with suspected restrictive lung disease or severe OSA

• Liver Biopsy: not routinely required but may be performed intraoperatively if NASH/cirrhosis is suspected

• Nutritional Assessment: dietitian evaluation and pre-operative high-protein, low-calorie diet (typically 2–4 weeks) to reduce hepatic volume and facilitate laparoscopic access

• Psychiatric/Psychological Evaluation: structured assessment using validated tools (e.g., BES scale for binge eating, PHQ-9 for depression)

CONTRAINDICATIONS:

• Severe, uncontrolled GERD or confirmed Barrett's esophagus (RYGB is preferred in these cases)

• Portal hypertension or significant cirrhosis (Child-Pugh B/C)

• Active malignancy or recent malignancy without oncology clearance

• Uncontrolled serious psychiatric illness or active substance use disorder

• Pregnancy or planned pregnancy within 18 months of surgery

• Severe coagulopathy or bleeding diathesis not amenable to correction

• Inflammatory bowel disease (relative contraindication; requires individualized assessment)

• Non-compliance history or inability to commit to post-operative follow-up and lifestyle protocol

STANDARD LAPAROSCOPIC SLEEVE GASTRECTOMY (LSG) — THE GOLD STANDARD: This remains the most commonly performed bariatric procedure globally, accounting for over 45% of all weight loss surgeries performed worldwide. The procedure is performed under general anesthesia. Using a 4–5 port laparoscopic approach, the surgeon mobilizes the greater curvature of the stomach from the pylorus (approximately 2–6 cm proximal) to the angle of His using an ultrasonic energy device (e.g., Harmonic Scalpel or LigaSure). A 36–40 French orogastric bougie is inserted transorally to calibrate the sleeve diameter. A series of sequential firings of a linear stapler (typically 60 mm cartridges, progressing from green/blue loads proximally) transect the stomach, creating a narrow tubular sleeve. The resected stomach specimen is extracted via one of the port sites. Staple-line reinforcement — either with absorbable bioabsorbable polymer buttress material or continuous seromuscular oversewing — is applied at the surgeon's discretion and per institutional protocol. Operative time averages 45–90 minutes. An intraoperative leak test using methylene blue dye or air insufflation under saline is standard.

ROBOTIC-ASSISTED SLEEVE GASTRECTOMY (da Vinci Xi / Medtronic Hugo RAS): Robotic platforms offer the operating surgeon scaled motion control, tremor elimination, and a magnified 3D-HD operative field. For sleeve gastrectomy specifically, the robotic approach facilitates more precise suture-line reinforcement, improved ergonomics during the angle-of-His dissection, and better visualization in super-obese patients (BMI > 55). Evidence suggests comparable or marginally superior staple-line integrity and equivalent weight loss outcomes to standard laparoscopy. Available at premium bariatric centers in India (Medanta, Fortis, Apollo) and UAE (Cleveland Clinic Abu Dhabi, Burjeel Medical City).

SINGLE-INCISION LAPAROSCOPIC SLEEVE (SILS / SILSS): A specialized technique performed through a single multi-port umbilical incision. Offers superior cosmetic outcome (essentially scar-free). Technically demanding and typically reserved for BMI < 50 in centers with specific SILS expertise. Longer operative time and higher surgeon skill threshold limit widespread adoption.

MINI-SLEEVE (FUNDUS-PRESERVING SLEEVE) — INVESTIGATIONAL: A modified technique that preserves a small portion of the fundus to theoretically reduce GERD risk post-operatively. Not yet widely validated or endorsed by IFSO as a standard approach; currently under evaluation in prospective trials.

REVISIONAL SLEEVE GASTRECTOMY: For patients who experience inadequate weight loss or weight regain after a primary sleeve (typically > 2 years post-op), revision options include: (1) Re-sleeve (reducing a dilated sleeve), (2) Conversion to Roux-en-Y Gastric Bypass (RYGB), or (3) Conversion to Single Anastomosis Duodeno-Ileal Bypass with Sleeve (SADI-S). Revisional surgery is significantly more complex, carries higher risk, and requires a thorough metabolic and anatomical workup including upper GI contrast study and EGD.

ADJUNCT PHARMACOTHERAPY (Pre- and Post-Operative): GLP-1 receptor agonists (e.g., Semaglutide/Ozempic, Liraglutide/Saxenda) are increasingly used as a bridge to surgery in super-obese patients to achieve pre-operative weight reduction and hepatic shrinkage, and as adjunctive post-operative therapy in cases of suboptimal weight loss. These agents must be discontinued at least 1 week prior to surgery due to gastroparesis risk.

INTRAGASTRIC BALLOON (Non-Surgical Bridge Option): For patients who do not yet meet surgical criteria or require pre-operative weight loss to reduce anesthetic risk, an endoscopically placed intragastric balloon (e.g., Orbera, Spatz3) can achieve 10–15% total body weight loss over 6 months. This is not a replacement for sleeve gastrectomy but may serve as a preparatory step.

PHASE 1 — PRE-OPERATIVE PREPARATION (4–8 weeks before surgery):

• Remote consultation with GAF Healthcare's bariatric coordinator and assigned surgeon; submission of medical records for candidacy review

• Completion of all required pre-operative investigations (endoscopy, ECHO, sleep study, blood panel — many of which can be done in your home country and uploaded digitally)

• Initiation of pre-operative liver-shrinkage diet (high-protein, low-carbohydrate, approximately 1,000–1,200 kcal/day for 2–4 weeks prior to surgery)

• Cessation of anticoagulants, NSAIDs, oral contraceptives, and GLP-1 agonists per surgical team timeline

• Visa and travel logistics coordinated by GAF Healthcare (e-Medical Visa for India; UAE entry visa or visa-on-arrival processing)

• Pre-operative psychological and nutritional counseling sessions (virtual or in-person upon arrival)

PHASE 2 — ARRIVAL & IMMEDIATE PRE-OPERATIVE PERIOD (Day -1 to Day 0):

• Airport transfer and check-in to partner hospital or pre-operative accommodation arranged by GAF Healthcare

• In-hospital pre-operative workup: anesthesia assessment, repeat fasting blood glucose, HbA1c, and INR; chest X-ray; DVT risk stratification using Caprini score

• NPO (nil per os) from midnight before surgery

• Pre-operative medication protocol: Proton Pump Inhibitor (e.g., Pantoprazole IV), prophylactic low-molecular-weight heparin (e.g., Enoxaparin) for VTE prophylaxis, and pre-emptive antiemetics

• Surgeon briefing and informed consent finalization

PHASE 3 — THE SURGICAL PROCEDURE (Day 0, approximately 1–2 hours):

• General anesthesia induction with rapid-sequence intubation (modified RSI for bariatric patients)

• Positioning: supine in reverse Trendelenburg, with split legs and padded pressure points (critical for super-obese patients)

• Trocar placement: typically 5 ports (10/12 mm umbilical camera port; 5 mm liver retractor; 12 mm and 5 mm working ports in left and right upper quadrants)

• Greater curvature mobilization from pylorus to angle of His using ultrasonic energy device

• Bougie placement (36–40 Fr) and sequential linear stapler firing

• Staple-line reinforcement and leak test

• Specimen extraction, port closure (fascial closure for ≥ 12 mm ports), and subcuticular skin closure

• Transfer to bariatric-specific ICU or step-down unit for 2–4 hours of monitoring before ward transfer

PHASE 4 — IN-HOSPITAL RECOVERY (Days 1–3):

• Day 1: Ambulation (sitting and short walks) within 6–8 hours of surgery; incentive spirometry every 2 hours; IV fluids and PPI; VTE prophylaxis (LMWH + compression stockings + pneumatic compression devices); pain managed with multimodal analgesia (IV acetaminophen, ketorolac, and low-dose opioid PRN)

• Day 1 evening/Day 2: Clear liquid diet initiated — water, clear broth, diluted juice; sip slowly, maximum 30 mL per sip

• Day 2: Surgical team review; drain (if placed) assessed for output/character; anti-nausea protocol (Ondansetron, Metoclopramide) continued

• Day 3: Discharge criteria met: tolerating ≥ 60 mL/hour of clear liquids, ambulating independently, pain controlled on oral analgesia, no fever, no tachycardia, drain removed

• Discharge with prescriptions: PPI (Omeprazole 40 mg daily for 3 months), LMWH (for 10–14 days post-discharge), chewable or liquid bariatric multivitamin, Vitamin B12 sublingual, calcium citrate + Vitamin D3

PHASE 5 — POST-DISCHARGE IN-COUNTRY RECOVERY (Days 4–21):

• Week 1 post-op: Full liquid diet (protein shakes, yogurt, thinned pureed foods); goal minimum 60g protein/day and 1.5 liters fluid; short walks increasing to 20–30 minutes; no lifting > 5 kg; no driving

• Week 2 post-op: Transition to pureed/soft foods (Week 2–6 protocol); wound check at Day 7–10 (staple/suture removal if non-absorbable)

• Surgeon follow-up appointment at Day 7–10 (in person in India/UAE) and a virtual follow-up at Day 14

• Post-operative upper GI contrast swallow study if any clinical concern (dysphagia, persistent tachycardia, fever) — this is NOT routine in uncomplicated patients

• Clearance for flight: physician review at 14–21 days post-operatively; cleared to fly when: tolerating adequate fluid and nutrition orally, no evidence of complication, wound fully healed, VTE risk mitigated (use of compression stockings mandatory on flight; recommend aisle seat and hourly ambulation)

PHASE 6 — LONG-TERM RECOVERY MILESTONES:

• 6 weeks: Transition to regular solid foods (small portions, slow eating); cleared for moderate exercise including swimming and cycling

• 3 months: Blood work (CBC, metabolic panel, iron, B12, D, PTH); assessment of diabetic medication reduction or cessation

• 6 months: Expected 40–50% excess weight loss; exercise regimen escalated

• 12 months: Peak weight loss phase (60–70% EWL); comprehensive metabolic and nutritional panel; psychological review

• 18–24 months: Weight stabilization phase; continued monitoring for GERD, hair thinning (telogen effluvium — typically resolves), and nutritional deficiency

• Lifelong: Annual blood work; permanent bariatric vitamin supplementation; dietary counseling